Pancreatic Cancer Research

ResearcherUniversity of ToyamaActive in the last 2 years

Juthamart Maneenet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9926-7092; OpenAlex author ID A5038438035. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2022: 3 papers · 2023: 4 papers · 2024: 1 paper · 2025: 4 papers · 2026: 1 paper

Papers 13

  1. Aporphine Alkaloid N-Nornuciferine from Nelumbo nucifera Induces MAPK-Associated Autophagy Under Nutrient Deprivation in Human Pancreatic Cancer Cells. First author DOI 10.3390/ph19091454↗
  2. Toyaburgine, a Synthetic N-Biphenyl-Dihydroisoquinoline Inspired by Related N,C-Coupled Naphthylisoquinoline Alkaloids, with High In Vivo Efficacy in Preclinic… First author DOI 10.1021/acschembio.4c00870↗
  3. Grandifloridin D: A Potent Antiausterity Agent Targeting Pancreatic Cancer Cells via Akt/mTOR and Autophagy Inhibition. First author DOI 10.1248/bpb.b25-00545↗
  4. Anti-cancer activity of 7-methoxyheptaphylline from Clausena harmandiana against PANC-1 pancreatic cancer cells and its sustainable extraction method. Co-author DOI 10.1371/journal.pone.0334901↗
  5. Calliviminone A from Callistemon citrinus Induces PANC-1 Pancreatic Cancer Cell Death by Targeting the PI3K/Akt/mTOR Pathway. Co-author DOI 10.3390/plants14132074↗
  6. Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro, and In Vivo Evaluations. Co-author DOI 10.1021/acs.jmedchem.4c01141↗
  7. Piper longum Constituents Induce PANC-1 Human Pancreatic Cancer Cell Death under Nutrition Starvation. Co-author DOI 10.1002/cbdv.202300280↗
  8. Dioncophyllidine E: The first configurationally semi-stable, 7,3'-coupled naphthyldihydroisoquinoline alkaloid, from Ancistrocladus abbreviatus, with antiauste… Co-author DOI 10.1016/j.bmcl.2023.129234↗
  9. Targeting Pancreatic Cancer with Novel Plumbagin Derivatives: Design, Synthesis, Molecular Mechanism, In Vitro and In Vivo Evaluation. Co-author DOI 10.1021/acs.jmedchem.3c00394↗
  10. Ugi Adducts as Novel Anti-austerity Agents against PANC-1 Human Pancreatic Cancer Cell Line: A Rapid Synthetic Approach. First author DOI 10.1248/bpb.b23-00224↗
  11. Design and synthesis of novel pipernonaline derivatives as anti-austerity agents against human pancreatic cancer PANC-1 cells. Co-author DOI 10.1016/j.bmc.2022.116963↗
  12. Abietane diterpenes from Abies spectabilis and their anti-pancreatic cancer activity against the MIA PaCa-2 cell line. Co-author DOI 10.1016/j.bmcl.2022.128723↗
  13. Chemical Constituents of Callistemon subulatus and Their Anti-Pancreatic Cancer Activity against Human PANC-1 Cell Line. Co-author DOI 10.3390/plants11192466↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suresh Awale · 13 shared papers, 2022–2026 · strength 2.87
  2. Tsutomu Fujii · 6 shared papers, 2022–2026 · strength 1.35
  3. Nguyễn Duy Phan · 7 shared papers, 2022–2025 · strength 1.32
  4. Hung Hong Nguyen · 5 shared papers, 2023–2026 · strength 1.26
  5. Naoki Toyooka · 4 shared papers, 2022–2024 · strength 0.68
  6. Ashraf M. Omar · 3 shared papers, 2022–2026 · strength 0.58
  7. Takuya Okada · 3 shared papers, 2022–2024 · strength 0.53
  8. Gerhard Bringmann · 2 shared papers, 2023–2025 · strength 0.43
  9. Yuki Fujihashi · 2 shared papers, 2022–2023 · strength 0.42
  10. Ahmed M. Tawila · 2 shared papers, 2022–2025 · strength 0.40
  11. Sijia Sun · 2 shared papers, 2022–2023 · strength 0.34
  12. Rawiwun Kaewamatawong · 1 shared paper, 2025 · strength 0.33
  13. Simon E. Lewis · 1 shared paper, 2025 · strength 0.30
  14. Takeyoshi Yamazaki · 1 shared paper, 2024 · strength 0.21
  15. Keisuke Tomohara · 1 shared paper, 2023 · strength 0.19
  16. Shaimaa Fayez · 1 shared paper, 2023 · strength 0.18
  17. Mitsuro Kanda · 1 shared paper, 2023 · strength 0.16
  18. Dya Fita Dibwe · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.